Anti-cancer drug discovery: Update and comparisons in yeast, Drosophila, and zebrafish

Current Molecular Pharmacology

Volumn 7, Issue 1, 2014, Pages 44-51

  Gao, Guangxun ^a,b   Chen, Liang ^a   Huang, Chuanshu ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Anti cancer drug discovery; Drosophila; HTS; Model organism; Yeast; Zebrafish

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; AD 58; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; INDIRUBIN 3' MONOXIME; LEFLUNOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NIMESULIDE; RAPAMYCIN; ROSUVASTATIN; SMALL MOLECULE ENHANCER OF RAPAMYCIN; SU 4312; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL MODEL; DROSOPHILA; DRUG DEVELOPMENT; DRUG IDENTIFICATION; DRUG SCREENING; DRUG TARGETING; GENETIC MANIPULATION; HIGH THROUGHPUT SCREENING; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; TOXICITY TESTING; TRANSCRIPTION REGULATION; TUMOR MODEL; YEAST; ZEBRA FISH; ANIMAL; HUMAN; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DROSOPHILA; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; SACCHAROMYCES CEREVISIAE; ZEBRAFISH;

EID: 84921922905     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467207666140702113629     Document Type: Article

References (68)

1. Sawyers, C. Targeted cancer therapy. Nature, 2004, 432, 294-297.
2. Wiedemann, L.M.; Morgan, G.J. How are cancer associated genes activated or inactivated. Eur. J. Cancer, 1992, 28A, 248-251.
3. Spring, D.R. Chemical genetics to chemical genomics: small molecules offer big insights. Chem. Soc. Rev., 2005, 34, 472-482.
4. Hartwell, L.H.; Szankasi, P.; Roberts, C.J.; Murray, A.W.; Friend, S.H. Integrating genetic approaches into the discovery of anticancer drugs. Science, 1997, 278, 1064-1068.
5. Barberis, A.; Gunde, T.; Berset, C.; Audetat, S.; Lüthi, U. Yeast as a screening tool. Drug Discov. Today Technol., 2005, 2, 187-192.
6. Giacomotto, J.; Segalat, L. High-throughput screening and small animal models, where are we? Br. J. Pharmacol., 2010, 160, 204- 216.
7. Davidson, A.E.; Balciunas, D.; Mohn, D.; Shaffer, J.; Hermanson, S.; Sivasubbu, S.; Cliff, M.P.; Hackett, P.B.; Ekker, S.C. Efficient gene delivery and gene expression in zebrafish using the Sleeping Beauty transposon. Dev. Biol., 2003, 263, 191-202.
8. Kurita, K.; Burgess, S.M.; Sakai, N. Transgenic zebrafish produced by retroviral infection of in vitro-cultured sperm. Proc. Natl. Acad. Sci. USA, 2004, 101, 1263-1267.
9. Wienholds, E.; Schulte-Merker, S.; Walderich, B.; Plasterk, R.H. Target-selected inactivation of the zebrafish rag1 gene. Science, 2002, 297, 99-102.
10. Lee, K.Y.; Huang, H.; Ju, B.; Yang, Z.; Lin, S. Cloned zebrafish by nuclear transfer from long-term-cultured cells. Nat. Biotechnol., 2002, 20, 795-799.
11. Stickney, H.L.; Schmutz, J.; Woods, I.G.; Holtzer, C.C.; Dickson, M.C.; Kelly, P.D.; Myers, R.M.; Talbot, W.S. Rapid mapping of zebrafish mutations with SNPs and oligonucleotide microarrays. Genome Res., 2002, 12, 1929-1934.
12. Ton, C.; Stamatiou, D.; Dzau, V.J.; Liew, C.C. Construction of a zebrafish cDNA microarray: gene expression profiling of the zebrafish during development. Biochem. Biophys. Res. Commun., 2002, 296, 1134-1142.
13. Botstein, D.; Fink, G.R. Yeast: an experimental organism for modern biology. Science, 1988, 240, 1439-1443.
14. Kumar, A.; Cheung, K.H.; Tosches, N.; Masiar, P.; Liu, Y.; Miller, P.; Snyder, M. The TRIPLES database: a community resource for yeast molecular biology. Nucleic Acids Res., 2002, 30, 73-75.
15. Foury, F. Human genetic diseases: A cross-talk between man and yeast. Gene, 1997, 195, 1-10.
16. Wahl, G.M.; Carr, A.M. The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat. Cell Biol., 2001, 3, E277-E286.
17. Simon, J.A.; Bedalov, A. Yeast as a model system for anticancer drug discovery. Nat. Rev. Cancer, 2004, 4, 481-492.
18. Perkins, E.; Sun, D.X.; Nguyen, A.; Tulac, S.; Francesco, M.; Tavana, H.; Nguyen, H.; Tugendreich, S.; Barthmaier, P.; Couto, J.; Yeh, E.; Thode, S.; Jarnagin, K.; Jain, A.; Morgans, D.; Melese, T. Novel inhibitors of poly(ADP-ribose) polymerase/PARP1 and PARP2 identified using a cell-based screen in yeast. Cancer Res., 2001, 61, 4175-4183.
19. Tentori, L.; Leonetti, C.; Scarsella, M.; D'Amati, G.; Vergati, M.; Portarena, I.; Xu, W.; Kalish, V.; Zupi, G.; Zhang, J.; Graziani, G. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin. Cancer Res., 2003, 9, 5370-5379.
20. Yashiroda, Y.; Okamoto, R.; Hatsugai, K.; Takemoto, Y.; Goshima, N.; Saito, T.; Hamamoto, M.; Sugimoto, Y.; Osada, H.; Seimiya, H.; Yoshida, M. A novel yeast cell-based screen identifies flavone as a tankyrase inhibitor. Biochem. Bioph. Res. Co., 2010, 394, 569-573.
21. Keith, C.T.; Schreiber, S.L. PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints. Science, 1995, 270, 50- 51.
22. Jacinto, E.; Hall, M.N. Tor signalling in bugs, brain and brawn. Nat. Rev. Mol. Cell Biol., 2003, 4, 117-126.
23. Bjornsti, M.A.; Houghton, P.J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer, 2004, 4, 335-348.
24. Aghajan, M.; Jonai, N.; Flick, K.; Fu, F.; Luo, M.L.; Cai, X.L.; Ouni, I.; Pierce, N.; Tang, X.B.; Lomenick, B.; Damoiseaux, R.; Hao, R.; del Moral, P.M.; Verma, R.; Li, Y.; Li, C.; Houk, K.N.; Jung, M.E.; Zheng, N.; Huang, L.; Deshaies, R.J.; Kaiser, P.; Huang, J. Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. Nat. Biotechnol., 2010, 28, 738-742.
25. Bier, E. Drosophila, the golden bug, emerges as a tool for human genetics. Nat. Rev. Genet., 2005, 6, 9-23.
26. Hay, B.A.; Huh, J.R.; Guo, M. The genetics of cell death: approaches, insights and opportunities in Drosophila. Nat. Rev. Genet., 2004, 5, 911-922.
27. Bernards, A.; Hariharan, I.K. Of flies and men--studying human disease in Drosophila. Curr. Opin. Genet. Dev., 2001, 11, 274-278.
28. Reiter, L.T.; Potocki, L.; Chien, S.; Gribskov, M.; Bier, E. A systematic analysis of human disease-associated gene sequences in Drosophila melanogaster. Genome Res., 2001, 11, 1114-1125.
29. Cenci, G.; Ciapponi, L.; Gatti, M. The mechanism of telomere protection: a comparison between Drosophila and humans. Chromosoma, 2005, 114, 135-145.
30. Gladstone, M.; Su, T.T. Chemical genetics and drug screening in Drosophila cancer models. J. Genet. Genomics, 2011, 38, 497-504.
31. Gonsalves, F.C.; Klein, K.; Carson, B.B.; Katz, S.; Ekas, L.A.; Evans, S.; Nagourney, R.; Cardozo, T.; Brown, A.M.; DasGupta, R. An RNAi-based chemical genetic screen identifies three smallmolecule inhibitors of the Wnt/wingless signaling pathway. Proc. Natl. Acad. Sci. USA, 2011, 108, 5954-5963.
32. Willoughby, L.F.; Schlosser, T.; Manning, S.A.; Parisot, J.P.; Street, I.P.; Richardson, H.E.; Humbert, P.O.; Brumby, A.M. An in vivo large-scale chemical screening platform using Drosophila for anti-cancer drug discovery. Dis Model Mech, 2013, 6(2), 521-529.
33. Dar, A.C.; Das, T.K.; Shokat, K.M.; Cagan, R.L. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature, 2012, 486, 80-84.
34. Sawamoto, K.; Okabe, M.; Tanimura, T.; Mikoshiba, K.; Nishida, Y.; Okano, H. The Drosophila secreted protein Argos regulates signal transduction in the Ras/MAPK pathway. Dev. Biol., 1996, 178, 13-22.
35. Guichard, A.; Biehs, B.; Sturtevant, M.A.; Wickline, L.; Chacko, J.; Howard, K.; Bier, E. Rhomboid and star interact synergistically to promote EGFR/MAPK signaling during Drosophila wing vein development. Development, 1999, 126, 2663-2676.
36. Gedaly, R.; Angulo, P.; Hundley, J.; Daily, M.F.; Chen, C.; Koch, A.; Evers, B.M. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res., 2010, 30, 4951- 4958.
37. Carracedo, A.; Ma, L.; Teruya-Feldstein, J.; Rojo, F.; Salmena, L.; Alimonti, A.; Egia, A.; Sasaki, A.T.; Thomas, G.; Kozma, S.C.; Papa, A.; Nardella, C.; Cantley, L.C.; Baselga, J.; Pandolfi, P.P. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest., 2008, 118, 3065-3074.
38. Streisinger, G.; Coale, F.; Taggart, C.; Walker, C.; Grunwald, D.J. Clonal origins of cells in the pigmented retina of the zebrafish eye. Dev. Biol., 1989, 131, 60-69.
39. Grunwald, D.J.; Eisen, J.S. Headwaters of the zebrafish-- emergence of a new model vertebrate. Nat. Rev. Genet., 2002, 3, 717-724.
40. Sprague, J.; Clements, D.; Conlin, T.; Edwards, P.; Frazer, K.; Schaper, K.; Segerdell, E.; Song, P.; Sprunger, B.; Westerfield, M. The zebrafish information network (ZFIN): the zebrafish model organism database. Nucleic Acids Res., 2003, 31, 241-243.
41. Meli, R.; Prasad, A.; Patowary, A.; Lalwani, M.K.; Maini, J.; Sharma, M.; Singh, A.R.; Kumar, G.; Jadhav, V.; Scaria, V.; Sivasubbu, S. FishMap: a community resource for zebrafish genomics. Zebrafish, 2008, 5, 125-130.
42. White, R.; Rose, K.; Zon, L. Zebrafish cancer: the state of the art and the path forward. Nat. Rev. Cancer, 2013, 13, 624-636.
43. Lessman, C.A. The developing zebrafish (Danio rerio): a vertebrate model for high-throughput screening of chemical libraries. Birth Defects Res. C. Embryo Today, 2011, 93, 268-280.
44. Murphey, R.D.; Stern, H.M.; Straub, C.T.; Zon, L.I. A chemical genetic screen for cell cycle inhibitors in zebrafish embryos. Chem. Biol. Drug Des., 2006, 68, 213-219.
45. Le, X.; Pugach, E.K.; Hettmer, S.; Storer, N.Y.; Liu, J.; Wills, A.A.; DiBiase, A.; Chen, E.Y.; Ignatius, M.S.; Poss, K.D.; Wagers, A.J.; Langenau, D.M.; Zon, L.I. A novel chemical screening strategy in zebrafish identifies common pathways in embryogenesis and rhabdomyosarcoma development. Development, 2013, 140, 2354-2364.
46. White, R.M.; Cech, J.; Ratanasirintrawoot, S.; Lin, C.Y.; Rahl, P.B., Burke, C.J.; Langdon, E.; Tomlinson, M.L.; Mosher, J.; Kaufman, C.; Chen, F.; Long, H.K.; Kramer, M.; Datta, S.; Neuberg, D.; Granter, S.; Young, R.A.; Morrison, S.; Wheeler, G.N.; Zon, L.I. DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature, 2011, 471, 518-522.
47. Yeh, J.R.; Munson, K.M.; Elagib, K.E.; Goldfarb, A.N.; Sweetser, D.A.; Peterson, R.T. Discovering chemical modifiers of oncogeneregulated hematopoietic differentiation. Nat. Chem. Biol., 2009, 5, 236-243.
48. Ridges, S.; Heaton, W.L.; Joshi, D.; Choi, H.; Eiring, A.; Batchelor, L.; Choudhry, P.; Manos, E.J.; Sofla, H.; Sanati, A.; Welborn, S.; Agarwal, A.; Spangrude, G.J.; Miles, R.R.; Cox, J.E.; Frazer, J.K.; Deininger, M.; Balan, K.; Sigman, M.; Muschen, M.; Perova, T.; Johnson, R.; Montpellier, B.; Guidos, C.J.; Jones, D.A.; Trede, N.S. Zebrafish screen identifies novel compound with selective toxicity against leukemia. Blood, 2012, 119, 5621-5631.
49. Yeh, J.R.; Munson, K.M.; Chao, Y.L.; Peterson, Q.P.; Macrae, C. A.; Peterson, R.T. AML1-ETO reprograms hematopoietic cell fate by downregulating scl expression. Development, 2008, 135, 401- 410.
50. Yamasaki, H.; Era, T.; Sanada, I.; Matutes, E.; Yamaguchi, K.; Takatsuki, K. High degree of myeloid differentiation and granulocytosis is Associated with T(8-21) smoldering leukemia. Leukemia, 1995, 9, 1147-1153.
51. Nakamura, H.; Kuriyama, K.; Sadamori, N.; Mine, M.; Itoyama, T.; Sasagawa, I.; Matsumoto, K.; Tsuji, Y.; Asou, N.; Kageyama, S.I.; Sakamaki, H.; EMi, N.; Ohno, R.; Tomonaga, M. Morphological subtyping of acute myeloid leukemia with maturation (AML-M2): Homogeneous pink-colored cytoplasm of mature neutrophils is most characteristic of AML-M2 with t(8;21). Leukemia, 1997, 11, 651-655.
52. Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov., 2007, 6, 273-286.
53. Tran, T.C.; Sneed, B.; Haider, J.; Blavo, D.; White, A.; Aiyejorun, T.; Baranowski, T.C.; Rubinstein, A.L.; Doan, T.N.; Dingledine, R.; Sandberg, E.M. Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish. Cancer Res., 2007, 67, 11386-11392.
54. Wang, C;, Tao, W.; Wang, Y.; Bikow, J.; Lu, B.; Keating, A.; Verma, S.; Parker, T.G.; Han, R.; Wen, X.Y. Rosuvastatin, identified from a zebrafish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer. Eur. Urol., 2010, 58, 418-426.
55. Chen, Y.H.; Wang, Y.H.; Yu, T.H.; Wu, H.J.; Pai, C.W. Transgenic zebrafish line with over-expression of Hedgehog on the skin: a useful tool to screen hedgehog-inhibiting compounds. Transgenic Res., 2009, 18, 855-864.
56. Zimmermann, G.R.; Lehar, J.; Keith, C.T. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today, 2007, 12, 34-42.
57. Lehar, J.; Stockwell, B.R.; Giaever, G.; Nislow, C. Combination chemical genetics. Nat. Chem. Biol., 2008, 4, 674-681.
58. Borisy, A.A.; Elliott, P.J.; Hurst, N.W.; Lee, M.S.; Lehar, J.; Price, E.R.; Serbedzija, G.; Zimmermann, G.R.; Foley, M.A.; Stockwell, B.R.; Keith, C.T. Systematic discovery of multicomponent therapeutics. Proc. Natl. Acad. Sci. USA, 2003, 100, 7977-7982.
59. Dunstan, H.M.; Ludlow, C.; Goehle, S.; Cronk, M.; Szankasi, P.; Evans, D.R.; Simon, J.A.; Lamb, J.R. Cell-based assays for identification of novel double-strand break-inducing agents. J. Natl. Cancer Inst., 2002, 94, 88-94.
60. Ivey, F.D.; Wang, L.; Demirbas, D.; Allain, C.; Hoffman, C.S. Development of a fission yeast-based high-throughput screen to identify chemical regulators of cAMP phosphodiesterases. J. Biomol. Screen, 2008, 13, 62-71.
61. Sangmalee, S.; Laorpaksa, A.; Sukrong, S. A topoisomerase II poison screen of ethnomedicinal Thai plants using a yeast cellbased assay. J. Ethnopharmacol., 2012, 142, 432-437.
62. Bedalov, A.; Gatbonton, T.; Irvine, W.P.; Gottschling, D.E.; Simon, J.A. Identification of a small molecule inhibitor of Sir2p. Proc. Natl. Acad. Sci. USA, 2001, 98, 15113-15118.
63. Hirao, M.; Posakony, J.; Nelson, M.; Hruby, H.; Jung, M.; Simon, J.A.; Bedalov, A. Identification of selective inhibitors of NAD+- dependent deacetylases using phenotypic screens in yeast. J. Biol. Chem., 2003, 278, 52773-52782.
64. Kadariya, Y.; Tang, B.; Myers, C.B.; Fukui, J.; Peterson, J.R.; Kruger, W.D. Chemical genetic screening for compounds that preferentially inhibit growth of methylthioadenosine phosphorylase (MTAP)-deficient Saccharomyces cerevisiae. J. Biomol. Screen, 2011, 16, 44-52.
65. Bhandari, P.; Shashidhara, L.S. Studies on human colon cancer gene APC by targeted expression in Drosophila. Oncogene, 2001, 20, 6871-6880.
66. Kim, B.H.; Yin, C.H.; Guo, Q.; Bach, E.A.; Lee, H.; Sandoval, C.; Jayabose, S.; Ulaczyk-Lesanko, A.; Hall, D.G.; Baeg, G.H. A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells. Mol Cancer Ther, 2008, 7, 2672-2680.
67. Gladstone, M.; Frederick, B.; Zheng, D.; Edwards, A.; Yoon, P.; Stickel, S.; DeLaney, T.; Chan, D.C.; Raben, D.; Su, T.T. A ranslation inhibitor identified in a drosophila screen enhances the effect of ionizing radiation and taxol in mammalian models of cancer. Dis. Model. Mech., 2012, 5, 342-350.
68. Li, Y.H.W.; Huang, S.; Du, J.; Huang, C. Screening of anti-cancer agent using zebrafish: comparison with the MTT assay. Biochem. Bioph. Res. Co., 2012, 422, 85-90.